MiNK Therapeutics Q3 2022 net loss $6.3M, cash $24.2M; pipeline and R&D day updates

MiNK Therapeutics, Inc.

2022-Q3 EPS reported -$0.60

Net loss $6.3M ($0.19/share) in Q3 2022 vs $14.3M ($0.59/share) in Q3 2021; nine-month loss $20.2M.
Cash $24.2M at Sep 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $14.4M in nine months.
Five abstracts accepted at SITC 2022; R&D day Nov 10, 2022 featuring external experts.
R&D expenses rose to $6.15M from $3.33M in Q3 2021 due to internal cGMP manufacturing scale-up.
No revenue or guidance; clinical-stage biotech advancing allogeneic iNKT cell therapies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MiNK Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.3 million or $0.19 per share, EPS $0.19 per share.

Period: the quarter ended September 30, 2022
Net income: $6.3 million or $0.19 per share
EPS: $0.19 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2022, was $6.3 million or $0.19 per share

View on SEC.gov

Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.